AstraZeneca rejects Pfizer talks, says confident in strategy
Britain’s AstraZeneca said it remained confident in its separate technique and advised its investors to take no action within the strategy by U.S. drugmaker Pfizer Inc on Monday.
Pfizer said earlier on Monday it’d created a 58.8 billion pounds ($98.9 billion) bid method of AstraZeneca in January and had approached its British competitor again on April 26 seeking further talks of a takeover.
“In this debate, the Chairman of Pfizer didn’t create a specific proposal regarding an offer to get AstraZeneca,” Astra said.
The British firm said it’d deemed the request talks, but with no attractive and distinct offer, it’d deemed it improper to participate in talks with Pfizer.
“The board remains confident in the continuing delivery of AstraZeneca’s strategy being an independent organization which its effective supply will generate substantial value for investors,” it said.